Chemeq posts $60.7m loss
24 August, 2005 by Ruth BeranAntimicrobial specialist Chemeq (ASX:CMQ) posted a $60.7 million loss for 2004-04, 509 per cent greater than the $9.9 million it posted in the previous financial year.
Mayne first to offer Medsaic's DotScan as leukaemia test
23 August, 2005 by Ruth BeranMayne Pathology (ASX:MAY) has agreed to provide Sydney-based Medsaic's DotScan test for leukaemia and lymphoma in four states in Australia, with an official launch of the technology at Mayne Health Laverty Pathology in Sydney today.
Pharmaxis to list on Nasdaq
23 August, 2005 by Ruth BeranDrug developer Pharmaxis (ASX:PXS) has received approval to list its American Depositary Receipts (ADRs) on the Nasdaq National Market under the symbol PXSLY.
Sirtex can't explain share surge
23 August, 2005 by Ruth BeranSirtex Medical (ASX:SRX) has been asked by the ASX to explain why its share price soared from $1.90 on August 15 to $2.45 on August 22.
Florigene plans blue rose field trials
23 August, 2005 by Graeme O'NeillMelbourne-based novelty flower developer Florigene is planning the first field trial of its genetically modified roses carrying the company's proprietary 'blue gene' technology.
Pfizer exec: what earlier licensing means for partnering
23 August, 2005 by Ruth BeranBig pharma is licensing new projects earlier, and that means prospective partners need to be creative, a Pfizer licensing director has told a Melbourne meeting.
Benitec and Promega settle litigation
22 August, 2005 by Ruth BeranRNAi specialist Benitec (ASX:BLT) and Wisconsin-based Promega have settled their contract dispute which began last year.
Ventracor implants second US patient
22 August, 2005 by Helen SchullerArtificial heart company Ventracor (ASX:VCR) has implanted its second VentrAssist left ventricular assist system (LVAS) in the United States.
Alchemia pleased with cash position, Bionomics revenues up
19 August, 2005 by Helen SchullerBrisbane biopharma Alchemia's (ASX:ACL) financial results for the year ending June 3 reveal that the firm has $15.9 million in the bank to support the development program of its lead anti-cancer drug candidate ACL 16907.
New VC fund launched in New Zealand
19 August, 2005 by Ruth BeranIt has been a big year for regional biotech-flavoured venture funds to be launched from New Zealand. The latest is Finistere Partners, a San-Diego based venture capital firm, which has launched a new fund targeted at agricultural biotechnology and medical devices.
EpiPharm psoriasis treatment recommended for PBS reimbursement
19 August, 2005 by Ruth BeranExorex, a non-steroidal treatment for psoriasis exclusively marketed in Australia by Epitan's (ASX:EPT) wholly-owned subsidiary EpiPharm, has been recommended by the Pharmaceutical Benefits Advisory Committee for Pharmaceutical Benefits Scheme (PBS) reimbursement.
NeuroSolutions to collaborate with Epichem
19 August, 2005 by Helen SchullerNeuroSolutions, a subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has entered into a collaborative agreement with Epichem, a subsidiary of PharmAust (ASX:PAA) to assist with the development of one of NeuroSolutions' lead pain drug candidates, NSL-036.
Polartechnics lands distribution deal for US laser product
18 August, 2005 by Ruth BeranSydney-based Polartechnics (ASX:PLT) has signed an exclusive agreement with Reliant Technologies to distribute the California-based company's Fraxel laser product range in Australia, New Zealand and Oceania.
Ventracor growth sends annual loss up 68%
18 August, 2005 by Ruth BeranArtificial heart company Ventracor (ASX:VCR) has posted a net loss of $AUD26.6 million for 2004-05, up 68 per cent from $15.9 million in the previous financial year.
Antisense CEO takes good with bad in end-of-year figures
18 August, 2005 by Helen SchullerMelbourne's Antisense Therapeutics (ASX:ANP) has reported a full-year after-tax loss of AUD$6.2 million, up from $4.6 million from last year, in results described by CEO Mark Diamond as "good news tinged with less than positive news".
